We have recently reported that #43 can enhance the anticancer activity of cisplatin in both estrogen receptor-positive and triple-negative breast cancer cells via enhancing the DNA damaging effect and modulating the Akt/mTOR and MAPK signaling pathways, which is at least in part associated with GLUT1 inhibition [33]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.